xbl novoskin preclinical study results, page-2

Billgeld,

Good post and sorry for the delay in replying as I have been away over the Christmas break, er., sorry, I meant HOLIDAY break (to pander to the politically correct).

The summary findings you posted are very encouraging.

The PolyNovo product appreciably outperforms the current market leader which allowed infection in 33% of the cases whereas the PolyNovo product had no trace of infection.

Also skin ulceration was apparently avoided in all cases using the PolyNovo product.

I'm not surprised that they held off the float.

As I mentioned in an earlier posting in 2007 they obviously had better news in the pipeline and look like putting it to good use to achieve the best price at the coming first quarter 2008 float.

(Sir) Lunchalot
Scoffer Extraordinaire